This trial is investigating whether a new diabetes treatment is better than a sham treatment at improving glycemic, hepatic, and cardiovascular outcomes for patients with type 2 diabetes who can't control their blood sugar with insulin therapy.
1 Primary · 0 Secondary · Reporting Duration: 24 Weeks
Active Control
Non-Treatment Group
560 Total Participants · 2 Treatment Groups
Primary Treatment: Duodenal Mucosal Resurfacing (DMR) · Has Placebo Group · N/A
Age 21 - 70 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 40.0% |
Arizona | 20.0% |
Texas | 20.0% |
Other | 20.0% |
18 - 65 | 66.7% |
65+ | 33.3% |
Mayo Clinic Arizona | 33.3% |
Mills Peninsula Health Center | 33.3% |
Baylor St. Luke's Medical Center | 33.3% |
Met criteria | 75.0% |
Did not meet criteria | 25.0% |
0 | 100.0% |
100.0% | |